# Dulaglutide REWIND trial: heart outcomes in type 2 diabetes

Source: https://pepvault.app/research/dulaglutide-rewind-2019

Last updated: 2026-11-17

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Research](https://pepvault.app/research) [Dulaglutide](https://pepvault.app/research#dulaglutide)

Randomized trial · people

# Dulaglutide lowered major cardiovascular events (HR 0.88) in REWIND

Checked against the paper November 2026 Randomized trial [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The takeaway

In a large, long trial of older adults with type 2 diabetes, dulaglutide led to fewer major cardiovascular events than placebo, but gut side effects were more common and overall deaths did not clearly differ.

- **Kind:** Randomized trial
- **Studied in:** People
- **Number studied:** 9901
- **Published:** 2019
- **Journal:** Lancet

## What they tested

Does adding weekly dulaglutide to usual diabetes treatment lower the rate of heart attacks, strokes and cardiovascular deaths in people with type 2 diabetes?

## How the study was done

A randomized, double-blind, placebo-controlled trial in 9901 adults aged at least 50 with type 2 diabetes who had either a past cardiovascular event or cardiovascular risk factors, run at 371 sites in 24 countries. Participants got a weekly injection under the skin of dulaglutide 1.5 mg or placebo (a dummy shot) and were followed for a median of 5.4 years.

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking dulaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=study-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What they found

The main outcome was a first non-fatal heart attack, non-fatal stroke or death from cardiovascular causes. It happened in 594 people (12.0%) on dulaglutide versus 663 (13.4%) on placebo, or 2.4 versus 2.7 per 100 person-years, giving a hazard ratio (a measure of relative risk over time) of 0.88 (95% CI 0.79-0.99). Death from any cause did not clearly differ: 536 (10.8%) versus 592 (12.0%), hazard ratio 0.90 (95% CI 0.80-1.01). Gut side effects were more common on dulaglutide, reported by 2347 people (47.4%) versus 1687 (34.1%) on placebo.

## What it doesn’t show

Only one dose, 1.5 mg weekly, was tested, and only in people aged 50 or older with type 2 diabetes and cardiovascular disease or risk factors. The trial was funded by Eli Lilly and Company.

## The paper

Gerstein et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019.

- [PubMed (PMID 31189511)](https://pubmed.ncbi.nlm.nih.gov/31189511/)
- [The paper (DOI 10.1016/S0140-6736(19)31149-3)](https://doi.org/10.1016/S0140-6736%2819%2931149-3)
- [ClinicalTrials.gov (NCT01394952)](https://clinicaltrials.gov/study/NCT01394952)

## The compound

- [Dulaglutide: how it works, half-life, studied range and evidence](https://pepvault.app/peptides/dulaglutide)
- [Dulaglutide dose guide](https://pepvault.app/lab/dosage/dulaglutide)

## With this study

### Dulaglutide

- [Dulaglutide: the full reference](https://pepvault.app/peptides/dulaglutide)
- [Dulaglutide dose guide](https://pepvault.app/lab/dosage/dulaglutide)

### Studies

- [Mazdutide beat dulaglutide on HbA1c and weight at 28 weeks](https://pepvault.app/research/mazdutide-guo-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [Dulaglutide cut HbA1c 1.3 vs 2.4 to 2.8 with tirzepatide at 52 weeks](https://pepvault.app/research/dulaglutide-surpass-j-mono-2022)
- [All 7 studies](https://pepvault.app/research#dulaglutide)

### Compared with

- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)
- [Tirzepatide vs Dulaglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-dulaglutide)

### Tools

- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)

## More studies on Dulaglutide

- [Mazdutide beat dulaglutide on HbA1c and weight at 28 weeks](https://pepvault.app/research/mazdutide-guo-2026) Randomized trial · people · 2026
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025) Randomized trial · people · 2025
- [Dulaglutide cut HbA1c 1.3 vs 2.4 to 2.8 with tirzepatide at 52 weeks](https://pepvault.app/research/dulaglutide-surpass-j-mono-2022) Randomized trial · people · 2022
- [Dulaglutide cut HbA1c and weight less than semaglutide in SUSTAIN 7](https://pepvault.app/research/dulaglutide-sustain-7-2018) Randomized trial · people · 2018
- [5-Amino-1MQ slowed bladder tumor growth in mice](https://pepvault.app/research/5-amino-1mq-yang-2024) Animal study · mice · 2024
- [MOTS-c prevented muscle atrophy, raised muscle glucose uptake in mice](https://pepvault.app/research/mots-c-kumagai-2024) Animal study · mice · 2024
- [Every study on Dulaglutide](https://pepvault.app/research#dulaglutide)

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed November 2026. Spot an error? [feedback@pepvault.app](mailto:feedback@pepvault.app). [How we research](https://pepvault.app/guides/how-we-research). This page reports one study; it is not medical advice.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=study-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking dulaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=study-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking dulaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=study-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this study

### Dulaglutide

- [Dulaglutide: the full reference](https://pepvault.app/peptides/dulaglutide)
- [Dulaglutide dose guide](https://pepvault.app/lab/dosage/dulaglutide)

### Studies

- [Mazdutide beat dulaglutide on HbA1c and weight at 28 weeks](https://pepvault.app/research/mazdutide-guo-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [Dulaglutide cut HbA1c 1.3 vs 2.4 to 2.8 with tirzepatide at 52 weeks](https://pepvault.app/research/dulaglutide-surpass-j-mono-2022)
- [All 7 studies](https://pepvault.app/research#dulaglutide)

### Compared with

- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)
- [Tirzepatide vs Dulaglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-dulaglutide)

### Tools

- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)

<!--promo-->

PepVault for iPhone

## Taking dulaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=study-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## Research

- [All studies](https://pepvault.app/research)
- [Every study on Dulaglutide](https://pepvault.app/research#dulaglutide)

## The library

- [Dulaglutide](https://pepvault.app/peptides/dulaglutide)
- [Dulaglutide dose guide](https://pepvault.app/lab/dosage/dulaglutide)
- [The peptide reference library](https://pepvault.app/peptides)

## How we work

- [How we research](https://pepvault.app/guides/how-we-research)
- [How we check the library](https://pepvault.app/about#library)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it. Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda, Victoza and Trulicity are trademarks of their respective owners; PepVault is independent and not affiliated with or endorsed by any manufacturer.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
